EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis

Alan Garcia iD, Abdul Mueez Alam Kayani, Daniel Alejandro Navarro-Martinez, Ricky E Lemus-Zamora, Richard Salama-Frisbie, Thomas Fretz, Eduardo Tellez-Garcia, Eduardo Aviles, Brijesh Patel

Cardiovascular Toxicology · 2026

DOI: 10.1007/s12012-026-10106-x ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cardiovascular Toxicology, 2026. Verfasst von Alan Garcia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Indiana University School of Medicine, 340 West 10th Street Fairbanks Hall, Suite 6200, Indianapolis, IN, 46202-3082…. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, was developed to overcome resistance from EGFR-mutant non–small-cell lung cancer (NSCLC). While it offers significant therapeutic benefits, reports have linked Osimertinib to cardiotoxic effects. This study aims to clarify the direct cardiotoxicity of Osimertinib by reviewing clinical trials and cohort studies involving Osimertinib monotherapy compared to other EGFR inhibitors. A search was conducted in online databases. Measured outcomes included risk of heart failure (HF), myocardial infarction (MI), decline in left ventricular ejection fraction (LVEF), arrhythmias, and pericardial effusion. These outcomes were reported as risk ratio (RR) with a random effects model using 95% confidence intervals (CI). Five studies with 19,008 patients (age 68 ± 13, 65% female) were selected. Osimertinib therapy was associated with an increased risk of HF (RR = 1.45, 95% CI 1.19–1.76, p = 0.0002), decline in LVEF (RR = 3.10, 95% CI 1.72–5.59, p = 0.0002) and MI (RR = 1.40, 95% CI 1.09–1.79, p = 0.0078) compared to other EGFR inhibitors. There was no difference in the risk of arrhythmias and pericardial effusion. Osimertinib therapy is associated with an increased risk of HF and a decline in LVEF compared to other EGFR inhibitors, while associations with MI and arrhythmias were less consistent. Although these events are infrequent, their potential severity warrants proactive cardiac monitoring for patients receiving Osimertinib, particularly in patients with pre-existing risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsAcrylamidesProtein Kinase InhibitorsAntineoplastic AgentsHeart DiseasesIndolesHumansErbB ReceptorsPyrimidinesCardiotoxicityFemaleRisk AssessmentVentricular Function, LeftRisk FactorsMaleTreatment OutcomeStroke VolumeAnimals

Stichwörter der Autor:innen

CarcinomaCardiotoxicityEpidermal growth factor/tyrosine kinase inhibitorsHeart failureMyocardial infarctionNon-small-cell lungOsimertinibReceptor

Substanzen

osimertinibIndolesAniline CompoundsAcrylamidesErbB ReceptorsPyrimidinesProtein Kinase InhibitorsEGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Indiana University School of Medicine, 340 West 10th Street Fairbanks Hall, Suite 6200, Indianapolis, IN, 46202-3082, USA. alangarc@iu.edu.
  • Department of Internal Medicine, AdventHealth Tampa, 3100 E Fletcher Ave, Tampa, FL, 33613, USA.
  • Department of Internal Medicine, Indiana University School of Medicine, 340 West 10th Street Fairbanks Hall, Suite 6200, Indianapolis, IN, 46202-3082, USA.
  • Department of Internal Medicine, Instituto Nacional de ciencias Médicas y Nutrición Salvador Subirán, CDMX, Vasco de Quiroga 15, Belisario Domínguez Secc 16, Tlalpan, Ciudad de México, 14080, México.
  • Department of Cardiovascular Medicine, Indiana University School of Medicine, 340 West 10th Street Fairbanks Hall, Suite 6200, Indianapolis, IN, 46202-3082, USA.

ORCID-Profile: Alan Garcia

Zitieren

APA

Garcia, A., Kayani, A. M. A., Navarro-Martinez, D. A., Lemus-Zamora, R. E., Salama-Frisbie, R., Fretz, T., Tellez-Garcia, E., Aviles, E., & Patel, B. (2026). Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-026-10106-x

Vancouver

Garcia A, Kayani AMA, Navarro-Martinez DA, Lemus-Zamora RE, Salama-Frisbie R, Fretz T, et al. Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis. Cardiovascular Toxicology. 2026. doi:10.1007/s12012-026-10106-x

BibTeX
@article{Garcia2026,
  author = {Garcia, Alan and Kayani, Abdul Mueez Alam and Navarro-Martinez, Daniel Alejandro and Lemus-Zamora, Ricky E and Salama-Frisbie, Richard and Fretz, Thomas and Tellez-Garcia, Eduardo and Aviles, Eduardo and Patel, Brijesh},
  title = {Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis},
  journal = {Cardiovascular Toxicology},
  year = {2026},
  doi = {10.1007/s12012-026-10106-x}
}
Kostenlos starten →